Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

SIGA Technologies, Inc. (SIGA)

7.19   0.07 (0.98%) 02-07 16:00
Open: 7.14 Pre. Close: 7.12
High: 7.21 Low: 6.955
Volume: 682,821 Market Cap: 525(M)

Technical analysis

as of: 2023-02-07 4:31:44 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 9.21     One year: 9.91
Support: Support1: 6.9    Support2: 5.74
Resistance: Resistance1: 7.88    Resistance2: 8.48
Pivot: 7.44
Moving Average: MA(5): 7.35     MA(20): 7.54
MA(100): 8.68     MA(250): 10.33
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 14.1     %D(3): 20.2
RSI: RSI(14): 42
52-week: High: 26.98  Low: 5.84
Average Vol(K): 3-Month: 821 (K)  10-Days: 591 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SIGA ] has closed above bottom band by 8.6%. Bollinger Bands are 67.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 86 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.21 - 7.25 7.25 - 7.29
Low: 6.87 - 6.91 6.91 - 6.95
Close: 7.13 - 7.19 7.19 - 7.25

Company Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Headline News

Wed, 08 Feb 2023
SIGA’s PlayNow Records Impressive Revenues, Sparking Gambling Harm Concerns - GamblingNews.com

Tue, 07 Feb 2023
FA’s chair Debbie Hewitt to headline at SIGA’s New York Summit on ... - Inside World Football

Tue, 07 Feb 2023
Monkeypox Treatment Market Strategic Assessment & SWOT ... - Digital Journal

Fri, 03 Feb 2023
In What Direction Will SIGA Technologies Inc.'s (NASDAQ:SIGA ... - The Dwinnex

Mon, 30 Jan 2023
Should You Accumulate SIGA Technologies, Inc. (SIGA) Stock Monday? - InvestorsObserver

Sat, 28 Jan 2023
Allspring Global Investments Holdings LLC sold shares of SIGA ... - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 74 (M)
Shares Float 39 (M)
% Held by Insiders 44 (%)
% Held by Institutions 43.8 (%)
Shares Short 4,860 (K)
Shares Short P.Month 5,470 (K)

Stock Financials

EPS 0.7
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.67
Profit Margin (%) 48.6
Operating Margin (%) 62.8
Return on Assets (ttm) 39.4
Return on Equity (ttm) 55.9
Qtrly Rev. Growth 92.5
Gross Profit (p.s.) 1.43
Sales Per Share 1.98
EBITDA (p.s.) 1.25
Qtrly Earnings Growth 0
Operating Cash Flow 72 (M)
Levered Free Cash Flow 58 (M)

Stock Valuations

PE Ratio 10.12
PEG Ratio 13.6
Price to Book value 4.27
Price to Sales 3.61
Price to Cash Flow 7.37

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.